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Objerdres . The long-term efficacy ano safety or a third .
generation implantable eardioverter-defhrilfator implanted with
thoracotooy and nonllmracotonmy lead syslens was evaluated in a
multicenter international study,
Bakgraand. The clinical Impact of transvenous leads for
noathoracotamy Implantation and pacing for hradyarrhytbmias
and tachyarrhythunias in implantable cardioverter-drgbritlator
sydeav Is ant well defined.
Methods. The safety of the implantation procedure and clinical
outcome of 1,221 patients seth symptomatic and tifalhreatersing
veotrkular tachyarehythmlas who underwent implantation of a
lbkd •geeeralba tardioverterdefibrjlater using either a tlmracot-
ney approech with epkanlLl leads (616 patients) or a ncothora-
eatomy approach with eadocardlel leads (615 patients) in a
eoaraedomiud matter was analyzed
. The implantable cardio-
letter-delibribtor system permitted pacing, cordinversion, defi-
brWatlon, arrhythmic event memory mall noninvasive tacbyrardia
Waterloo.
Results . SucceuM lmptantetion of an endaardial lead system
was achieved to 605 (8&2%) of 686 patients and ad epicardial
system In 614 (49.7%) of 616 (p < 0.05) . Perioperative 30-day
Implantable cardioverter-defibrillator systems are being of-
fered as a potential therapeutic solution to the enormous
health care dilemma of sudden unexpected cardiac death .
The optimal technology, implantation techniques, clinical
benefits, risks and costs of this therapy ace still being
defined. The clinical outcome of patients with malignant
ventricular tachyarrhythmias or sudden cardiac death
treated with nonprogrammahle implantable cardioverter-
defibrillators has been widely
reported (1-3). These devices
have almost exclusively used epicardial lead systems requir-
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mortality rate was 0,8% (1
.8% including crcrtsrves) in eadocar
dial implant recpients compared with 4.2%
(p
w
(1,001) in
epicardial implant recipients (3 .6% without crossovers, p < 0
.
.15,
respectively)
. tenplantatioa mortality risk was signifcatly tower
for nonthoracritomv systems irrespective of left venhicular ejec .
lion fraction or New York Hears Association llmdioaal clam .
Pacing therapies prevented need for cardiaversioa or defibrilla-
tion shocks in 89% of alt venlrleutar tae :4eardia episodes and
were eampuesbly effective for both lead systems. Total survival
rate at 2 years was significantly higher in endocardlal (87,60
than epkardial (819%) lead recipients (p < 0 .001) . Elimination
of pedoperative modality from the analysis demonstrated com-
parable survival in both groups (p > 0.2)
.
Contusions . Third-generatico eardlovereer-defbrlltatms with
manophasic waveforms can he successfully implanted with epkar
dial (99.7%) and eoducardtal (68.2%) lead systems. We conclude
that endarardial leads should be the implant technique of first
ranks . Improved patient management and Interlace for device
therapy is achieved with the addition of antitaduvrardia pace-
maker capability in these systems .
(J Am Coll Cerdiol 1944;23:1521-30)
ing thoracotemy, with an
estimated generator life of 2 years
.
It is estimated that 20,000 implantation are performed annu-
ally at an estimated cost of $I billion . A significant part-
operative risk for implantation of the implantable catdioverter-
defibrillator system by the epicardial approach has been
recognized
. This has ranged from 1% to 10% mortality rate
at individual centers, with multicenter rates ranging from 2%
to 5% (4-8). This level of patient risk for device implantation
can equal the subsequent risk of sudden death after device
implantation ever several years . Endocardial lead systems
were first clinically applied with implantable cardioverter-
defibrillator devices 7.5 years ago, and they have been widely
expected to simplify implantation procedures, eliminate the
need for a thoracotomy and increase patient acceptance of
devicesystems(9,10). Newerdevelopmentscombiningbrady-
cardia or antitachycardia pacing with cardiaversion or defi-
brillation in this generation
of
implantable cardioverter-
defibrillators will further these goals (It, 12). The impact of
6
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this development on the safety of the implantation procedure
and clinical results with these systems is unknown. In this
report, we examined the implantation risks and subsequent
clinical outcome in 1,221 patients who received a third-
generation implantable cardioverter-defibrillator using either
epicardial leads (616 patients) requiring a thoracotomy or
endocardial leads (605 patients) not requiring thoracotomy
who were enrolled in a prospective international multicenter
clinical trial . This study also reports a worldwide multicenter
experience with a third-generation implantable cardioverter-
defibrillator with demand and antitachycardia pacing, car`
dioversion and defibrillation capabilities .
Methods
Patktu seketlon. Patients were enrolled if one or more of
the following selection criteria were fulfilled: 1) documented
cardiac arrest or ventricular fibrillation unrelated to transient
or reversible clinical events with clinical and electrophysio-
logic evaluation that suggested that the patient was at risk for
recurrent cardiac arrest; and 2) sustained, dmg•refiactory
ventricular tachycardia . Sustained for purposes of this study
was defined as ventricular tachycardia >30 a duration and
refractoriness as either spontaneous ventricular tachycardia
recurrence, induction of sustained ventricular tachycardia at
electrophysiologic study or intolerance to the antiarrhythmic
agent . Patients were advised as to the nature of the study
procedur s and follow-up. Written informed consent for
device implantation and all study procedures during the
implantation hospital period and follow-up was obtained.
Patients received epicardial leads initially because this sys-
tem tzcsme available first for implantation on May 11, 1999
.
Endocardial leads became available for implantation on
October 20, 1989, After availability of both systems, lead
selection was at tile investigator's discretion,
Exclusion criteria for this study included I) refractory
supraventricular arrhythmias with rapid ventricular rates
despite amiarrhylhmic drug therapy ; 2) ventricular tachycar-
dia or ventricular fibrillation due to proarrhythmic effects of
antiarrhythmic drugs, as determined by individual investi-
gators on the basis of
clinical or relevant data, or both ;
3) ventricular tachycardia or ventricular fibrillation due to
metabolic or electrolyte abnormalities, recent acute myocar-
dial infarction or myocardial ischemia; 4) frequent, nonsus-
tairred ventricular tachycardia or incessant .. sustained ven-
tricular tachycardia ; 5) patients with a projected life
expectancy <6 months at the time of consideration of device
therapy ; and 6) patients unwilling to comply with device
follow-up procedures for medical or administrative causes
.
Implantable pacemaker•ardieverter•defibrllator ayuem .
The implantable device system included a pulse generator
(Medtronic models 7216A and 72170) and an epicardial or
endocardiul lead system (I1) .
The device can be externally
interrogated and programmed
. The pulse generator is an
implantable multiprogrammable device that permits auto-
matic detection and termination of ventricular tachyarchyth-
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mias, tachycardia induction with noninvasive programmed
stimulation, demand bradycardia pacing and telemetric eval-
uation of device variables. Tachycardia detection is accom-
plished on the basis of ventricular rate . The device monitors
intervals between consecutive ventricular complexes and
classifies them into three zones defined by two preset
intervals . These three zones consist of sinus rhythm, ven-
tricular tachycardia or ventricular fibrillation . Sinus rhythm
is differentiated from ventricular tachycardia by a tachycar-
dia detection interval and ventricular fibrillation by a fibril-
lation detection interval. These can be programmed from 280
to 600 ms. Furthermore, these criteria can be further quali-
fied by he additional requirement of sudden onset of the
tachycardia detection interval or rate stability during the
tachycardia . The details of device detection and therapy
variables, programming options and function have been
reported elsewhere (11). Episodes defined as ventricular
tachycardia by the device result in preparation for adminis-
tration of the preselected electrical therapy but require
reconfirmation of tachycardia before delivery of therapy
.
Episodes defined as ventricular fibrillation by the device
proceed to delivery of therapy without reconfirmation . Elec-
trical therapies available for tachycardia termination are
programmed according to the recognized twhyarrhythima.
Ventricular tachycardia can be cardioverted by programmed
rapid pacing modes as well as synchronized shocks ranging
in energy from 0.2 to 341 . Ventricular fibrillation is reverted
by delivery of synchronous or asynchronous shocks . Each
therapy can be individually programmed, as previously
reported (11). The genetatordelivers monophasic, truncated
exponential shocks over dual- or triple-electrode configura-
tions in epicardid or endocardial locations. Single, simulta-
neous or sequential shock delivery options are available (11) .
The generator memory contains a summary tithe number of
ventricular tachycardia and ventricular fibrillation episodes
with information regarding individual therapies and their
outcome . It maintains a record of the last tachyarrhythoria
episode with the detected RR intervals as well as the type of
therapy administered and most recent charge time and
permits interrogation of battery and circuit voltages. The
sensed ventricular electrogam can be telemetered . and a
marker channel for sensed and paced events can be ob-
tained . In addition, the device can be driven by the external
programmer for noninvasive electrophysiologic testing .
The lead system utilizes a dual- or tripleelectrode con-
figuration for cardioversiondefibritlation and an integrated
or close bipolar electrode configuration (models 7216A and
7217B, respectively) for pacing and sensing. The choice of
dual. or triple-electrode systems was at investigator discre-
tion. The cardioversiondefibrillation electrodes consist of
either oval epicardial electrodes or endocardial pacing and
defibrillation catheter electrodes used in conjunction with a
subcutaneous patch electrode and has been reported else-
where (11)
.
The sensing and pacing epicardiat electrodes)
consists of one or two screw-in or stab-in standard epicardial
electrodes(s) (11). Endocardial pacing and sensing utilized
JACC Vol. 23, Nn . 7
rune 1994: 152 1-30
bipolar electrodes at the distal tip of the ventricular lead
. The
external programmer is a software-driven programmer with
a wand that can be coupled to the pulse generator. Its
function has also been previously detailed (I1)
.
Eketrophysiologic evaluation and device Implantation
.
The study design required entry of patients meeting inclu-
sion criteria who were undergoing etectrophysiologic evalu-
ation before device implantation. All patients in this study
underwent baseline electrophysiologic evaluation
in a drug-
free state . Choice of lead system implant was dictated by
device availability from the manufacturer and release by
governmental regulatory agencies in each
nation . Surgical
implantation of an epicardial lead system was accomplished
by sternotomy or thoracotomy using standard techniques
(6) . The endocardial electrode system was inserted from the
cephalic or subclavian vein
(I1). Two cndocardial electrode
catheters were placed in the right ventricle
and either the
right atrial-superior venacaval junction or the coronary
sinus. The subcutaneous patch electrode was placed on the
anterior left thorax. Details of the epicardial
implantation
technique and the endocardial electrode placement tech-
nique and testing methods have been described elsewhere
(11) . Three of four consecutive successful ventricular de-
fibrillations at energies sill J were required for device
implantation . The defibrillation threshold at implantation
was defined as the lowest successful energy for ventricular
fibrillation termination, with demonstrated failure at a lower
energy level . For patients undergoing bypass surgery, these
were measured after revascularizatiou . Successful conver-
sion at 5 J was accepted without need for failure at lower
energies
.
Felew-up
. Postoperative electrophysiologic evaluation
was performed S to 7 days after system implantation during
the discharge drug regimen . Reprogramming was performed
if indicated. If the system performance was satisfactory, the
patient was discharged. Outpatient clinic follow-up included
clinic visits at I month and every
3 months thereafter .
During follow-up, patients were instructed to report sponta-
neous tachycardia events, symptoms (e .g ., palpitations,
syncope or presyncope) as well as any shuck therapy .
Auulysls of resdb. The study end points included death
from any cause, categorized as indicated later, or completion
of follow-up that was cut off on May l4, 1992, for epicardial
lead systems and June 24, 1992, for endocardial
lead sys-
tems
. This difference was due to timing, when all follow-up
data could be fully compiled for each cohort .
Perioperative mortality was defined as ail-cause mortality
within a id-day interval after ingrtan .able cardieverter-
defibrillatcr system implantation . Sudden cardiac death in
this study was defined as sudden, unexpected death occur-
ring without symptoms or within I h of onset of symptoms
and included unwitnessed death .
Cardiac mortality included
mortality from all causes determined to be cardiac in nature
and included sudden death . The definition of cardiac mor-
tality excluded accidental causes, malignancy or other non-
cardiac etiologies . Nonsudden deaths were defined as those
SAKSENA Er AL .
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occurring > 1 h after onset of symptoms . Noncardiac deaths
were those where the primary cause of death was deter
mined not to be cardiac in nature . Proced -e-related deaths
were those that occurred directly as a result of procedures
required to implant or test of the device system during
follow-up
. Deaths were class ified after review of clinical,
electrocardiographic and,
if indicated, electrophysiotogic
and device data log information by individual investigators .
They were reviewed by the Study Clinical Event Review
Committee for accuracy. Sudden, cardiac and total survival
curves after implantable cardioverter-defibrillator system
implant are presented using the Kaplan-Meer life table
method for actuarial analysis . perioperative mortality was
included in total survival data
. Complications were defined
as symptomatic or asymptomatic clinical
conditions with
potential adverse effects requiring device system revision for
correction. Clinical observations are defined as symptomatic
or asymptomatic clinical conditions with potential adverse
effects correctable by
system reprogramming or other
therapeutic interventions but did not require implantable
cardioverter-defibrillator system revision .
Results
Patient population. Twelve hundred twenty-one patients
with sustained ventricular tachycardia or ventricular fibril-
lation were enrolled in this study (mean age was 59 .4 years;
1,016 men, 205 women). Nine hundred twenty-eight
patients
had coronary artery disease, 368 had congestive cardiomy-
opathy, and 202 had both . Mean (±SD) left ventricular
ejection fraction was 34.9 ± 14 .5%. Nine hundred seventy-
seven patients were in New York Heart Association func-
tional class I or Ii; 205 were in functional class Ill ; and 12
were in functional class IV . Indications for implantable
cadioverter-defibrillator implantation were recurrent, sus-
tained ventricular tachycardia in 621
patients (50.9%), sur-
vival of sadden cardiac arrest in 423 patients (34.6%) and
both in 177 patients (14 .5%).
Table I compares the clinical characteristics of 516 pa-
tients who underwent actual implantation of an epicardia
lead system with the Medtr^vic 72I6A or 7217B pulse
generator with 605 patients who underwent implantation of
an endocardial nonthoracotomy lead system with the same
generator . The two groups were comparable for age, cardiac
disease status and functional class. Female gender and
sudden cardiac death as an indication for implantation was
slightly more frequent in the endocardial group . Conversely,
recurrent, sustained ventricular tachycardia was the more
common indication in the epicardial group . The incidence of
sustained ventricular tachycardia and sudden cardiac death
was lightly more frequent in the epicardial group
. Actiar-
rhythmic drug trials before device implantation were more
extensive in the epicardial group. Mean left ventricular
ejection fraction was slightly lower in the epicadial group
(33.7 ! 14.1%) compared with the endocardial group (35
.9
14
.8%).
1
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Table 1 . Clinical Chamolorislics of the Palieat Population
Endocardial System E6caidial System
Total lmdant
Recipients eeoplenls Reclpienls
'sta6a,callystart,&ant .endacardlalvernneprardlalrerlplems .'Sal, pxfrdm27713011s .(- AD=co-y
leery
4)11010 : f VFF a tell realnelllar edeelrnn fraelln: NYHA = nea r Turk Hem Ascnnlaliee : Ns= pallenm:
stn - sudden cardiac dealt : VT = venmcuar lachyramla,
Implantation observations. Six hundred eighty-six pa-
tients underwent attempted implantation of the endocardial
lead system . This lead system could be implanted in con .
junction with a model 72 16A or 72178 pulse generator in 605
patients (88 .2%). Eighty-one patients who did not have
successful implantation ofthe endocardial lead system sub,
sequenlly underwent successful implantation of an epicar-
dial lead system. Of 616 attempted epicardial implants,
successful implantation of epicardial lead system and pulse
generator was achieved in 614 patients (99 .755), Leads only
were Implanted in two patients . Four hundred-forty patients
(72,7%) net the implant criterion of IS J with the chosen
endocardial lead system, wherea 340 patients (87 .7%) met
the same criterion with an epicardial lead system (p < 0 .05).
The remainder of the implantation were performed on the
basis of investigator decision to proceed with individual
implantable cardioverter-defibrllator system implantation .
A triple-electrode configuration was implanted in 99,5% of
endocardial systems, whereas this was implanted in only
45.6% of epicardial systems (p < 0 .001)
. Triple-electrode
configurations most commonly used for shock delivery with
endocardial lead systems were right ventricular cathode with
dual anodes in the superior vena cava and subcutaneous
patch in 65 .6%a ; a right ventricular cathode with coronary
sinus and subcutaneous patch anodes was used in 29
.4%;
and right ventricular cathode with superior versa, cave and
coronary sinus anodes was used in 5 .11%8. Of the epicardial
lead systems, 34
.7% actually utilized the three epicardial
patches for shock delivery, usually with a left ventricular
cathode and dual anodes on the anterior and posterior right
and left ventricle. Two epicardial patches alone were utilized
for shock delivery in 65 .3% or implants. Concomitant car-
disc surgery at the time of defibrillator system implantation
was performed in 14.6% of patients undcrgoilrg epicardial
lead system implantation but was not performed in any
patient undergoing endocardial lead system implantation
(p c 0,001) . Antiarrhythmic drug therapy was administered
at device implantation in 248 patients (41%)
receiving
endo
cardlel leads and 313 patients (50.8%) receiving epicardial
leads (p = 0.001) . The mean defibrillation threshold at
implant was 14 .4
a
5,43 forall endocardial lead systems and
9 .6 t 5 .11 for epicardial leads
(p
< 0.0011-
Pertrperative mortality rote was 4 .2%
for
all patterns
undergoing epicardial lead system and generator implanta-
tion
and 0.8% for all patients undergoing erdocardial lead
system and generator implantation (p < 0 .001). When an
intention-to-treal approach was used Mail included endacar-
dial implant recipients crossing over to receive epicardial
implants in the endocardial group, the perioperative mortal-
ity rate of endocardial lead implantation Increased to 1 .8%,
whereas the epicardial lead system declined to 3 .6% (p <
0.03)• The implantation mortality risk was decreased in all
patients . Table 2 shows specific factors, such as functional
class or left ventricular function, for implantation mortality .
Patients are stratified by functional class and left ventricular
ejection fraction in patients with available data . Implantation
morWhy risk for both lead systems increased with func-
tional class IIIItV or left ventricular ejection fraction <30%.
Decreased implantation mortality risk for endocardial lead
systems was observed in patients with a left ventricular
ejection fraction >50% or s3058, functional classes I and 11
and classes Ill and IV . The perioperalive mortality rate in
patients who had direct endocardial implantation without
crossover (primary implantation, 605 patients) was 0-S%,
No. of it ;4 No. ,rpi, No. of Pi, 90 p Value
Mean see lyr
;
54.3 59.6 59 .4 0.6921
Male 489 60.8 32, 65.6 11016 83.2 0 .028
Femme 116 19.2 89 144 205 16.8
CAD 449 74 .2 479 778 928 76.0 0 .147
Cueiomyopolhy 190 31 .4 178
79 .9
368 30.1
0
.379
Primary indications
SCD 239 39 .5 184 29.9 423 34.6 0 .0)2
VT 287 47.4 334
54 .2
621 50.9
SCDandVT 79
13 .1 98
159 177 14 .5
P. v4 cdose4e,opy' 2,5 3 .0 2.6 0 .0))
NYHA funtti
and rime+
bit
4e8 33.a 469 80,7 977 81,8 0.148
111 91 IS •1 114 18 .6 205 17,2
IV 9 I .3 3
0
. 12 1 .0
MeanLOOP(Yo)' 399 357 10010 11140
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Table 2 . Stratification of Perioperative Mortality
'p s 0.001, 'p s 0 .01 and tp <_ 0,05 . New York Hear Association
(NYHA) fne6onal class till versus 10903001 class AVIV or loll ventricular
ejection fraction (LVEF) 930% versus >30% .
.md direct epicardial lead implantation (primary implanta-
tion, 535 patients) was 3.6%
. In the 81 patients who had
endocardial lead implantation attempted before epicardial
lead insertion (secondary implantation), the perioperative
mortality rate was 8.6% (p < 0 .05 vs. direct endocardial or
epicardial implantation).
Device programming. The initial ventricular tachyar-
rhythmia therapy programmed with endocardial and epicar-
dial lead systems is shown in Figure I . Ventricular lachy-
Figure 1. Top, Programming for ventricular tachyeardia
(VT) and ventricular fibrillation (VF) therapies (RX) as
defined by the device or demand ventricular pacing in the
study population at follow-up . Ventricular tachycardia
therapy is independently programmed in addition to yen.
tricolor fibrillation therapy in the VT RX ON group
.
Ventricular fibrillation therapy is used alone in the VF RX
ONLY group. Neither was used, but Demand ventricular
pacing was active, in the VVI ONLY group . INACTIVE _
patients with active antitachycardia therapies . Bottom,
Initial electrical therapy for ventricular tachycardia or
ventricular fibrillation stratified by lead system for study
population . ATP = antitachycardia pacing for ventricular
tachycardia .
90
e0
40
20
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cardia therapy was independently programmed as distinct
from ventricular fibrillation therapy in 65% of patients . Note
that frequency of ventricular tachycardia and ventricular
fibrillation therapies being separately programmed and acti-
vated was comparable at the time of analysis in both groups
(Fig. I, top) . Ventricular fibrillation therapy alone was used
more often in the endocardial than epicardial group
. More
patients were classified as inactive (i .e ., device therapies
were turned off, or patients had died at the time of study
cutoff) in the epicardial group because of the higher overall
patient mortality . Programming of ventricular tachycardia
therapy to antitachycardia pacing modes and cardioversion
shock was noted to be comparable across the entire range for
both lead systems (Fig
. l, bottom). The shack pattern used
was different across lead systems . Sequential and simulta-
neous shocks were used more frequently in the endocardial
system (98.4% vs. 34 .8%, p < 0.01), whereas single shocks
were more common in the epicardial system (65 .3% vs.
1.6%, p < 0 .01). This is due to the higher prevalence of
triple-lead configurations in the endocardial systems and
dual lead configurations in the epica dial systems . Low
energy (<2 J) shocks were used for tachycardia reversion in
the ventricular fibrillation zone in only 0.2% of endocardial
and 1% of epicardial implants . This reflects usage of this
% PATIENTS
inn
98 .7
J 0.2 1 1.1
ATP-RAMPATP-13URSTVT SHOCK VF '2J
VF '10J VF 110J
Lead System Implanted
p Value
(mudnc .rd
al vs .
ericardiall
Endocardial
(%(
Epicardial
(`71
NYHA functional class
VII 0 .2 3 .3
< 0.001
IIVIV 3 .9' 77-
<0.001
LVEF
<30% 2 .1 52 < 0.941
03050 at 34 < 0 .001
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therapy for rapid ventricular tachycardia in this detection
zone . Intermediate energy shocks (2 to 10 J) were used for
rapid ventricular tachycardia or ventricular fibrillation in
1 .1% of endocardial and 8 .8% of epicardial implants
.
Clinical outcome. Figure 2 shows the clinical outcome of
patients receiving epicardial and endocardial lead systems
during a mean follow-up period of 9 .5 ± 8 .3 (range 0 to 33)
and 5 .9 ± 5 .5 (0 to 29) months, respectively. Actuarial
survival analysis shows a sudden death-free survival rate of
97.3% and total survival rate of 81 .9% at 2 years for the
epicardial lead system. The corresponding values for the
endocardial lead system are 99.8% and 87 .6%. There is a
significant difference between lead systems for 6-, 12- and
24-month total survival . There is also a trend to better
sudden death survival at 1 year (p = 0
.06), becoming
significant by 18 and 24 months (p < 0 .04) in the endocardial
lead recipients
. When perioperative events are excluded,
analysis of cardiac and noncardiac mortality in the two
patient groups is comparable for 36 months of follow-up
30 33 3e
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Flgare 2. Long-term actuarial survival of study popu-
lation stratified by implant technique .
Top,
Sudden
death and total survival, including perioperative mor-
tality for endocardial (ENDO) and epicardial (EPI)
lead systems. Significance of difference between sub-
groups at 6. 12, 18 and 24 months of follow-up are
indicated by p values. Bolos, Cardiac and noncardiac
mortality in study population after device implanta-
tion. Perioperative morality was excluded in this
analysis.
(Fig. 2, bottom) . There was no difference in survival be-
tween patients meeting the implant criteria of I8 J with
endocardial leads and the remainder of the patients with the
implantable cardioverter-defibrillator system.
ArrhytBwlaeventsdmigfolow .up . Three hundred nine-
teen patients with epicardial lead systems had spontaneous
events (51 .8%) compared with 254 patients (42%) with
endocardial lead systems . This difference could reflect dura-
tion of follow-up . The total number of ventricular tachycar-
dia episodes logged was 11,210 for epicardial devices and
4,778 for endocardial devices . The total number of ventric-
ular fibrillation episodes logged was 1,223 for epicardial lead
systems versus 816 for endocardial lead systems . The mean
number of ventricular tachycardia episodes per patient was
greater with the epicardial (n = 35) than the endocardial (n =
19) lead system . The number of ventricular fibrillation epi-
sodes, however, in the two groups was comparable
. Effec-
tive ventricular tachycardia reversion was achieved in 98 .2%
of all episodes for the epicardial system and 98 .7% of
•Data are mean values or number t% of patients . ICD = implanrable
eardiovener-defibrillator, other abbreviations as in Table I .
episodes with the endocardial system
. Ventricular tachycar
dia reversion in the entire study population was achieved
with antitachycardia pacing in 14 .301 (89.4%) of 15,985
episodes
. The frequency of effective reversion was compa-
rable for both lead systems (88.5% for epicardial vs . 91 .7%
for endocardial, p > 0.2). Romp pacing was effective in
91
.4% (endocardial) and 90
.8% (epicardial) of all tachycardia
episodes (p > 0 .2)
.
Burst pacing was effective in 90 .7%
(endocardial) and 86.4% (epicardial) of treated episodes (p >
0 .2) . Shock therapy was used for ventricular tachycardia
reversion in 11 .5% of episodes in epicardial lead recipients
and
8 .3p%n of episodes in endocardial lead recipients (p >0 .2).
Ventricular fibrillation reversion was achieved in 98
.4% of
episodes with the epicardial system and 98.9% of episodes
with the endocardial system (p > 0.2) . Device therapy was
delivered inappropriately far atria( fibrillation on the basis of
clinical and event counteranalysis equally frequently in both
endocardial and epicardial implant recipients (1 .5% of all
ventricular fibrillation episodes, p > 0.2). Corresponding
numbers for ventricular tachycardia therapy were 4 .1% nod
4.9% (p > 0.2).
Study deaths and complications. Table 3 shows an analy-
sis of total mortality in this study . Patients were compared
on the basis of device implantation technique with respect to
clinical characteristics and the nature of mortality observed
during follow-up. The mean time interval from implantation
to death was 107
.
153 days in endocardial and 147 ± 177
days in epicardial implant recipients .
Complications requiring system revision and clinical ob-
servations requiring reprogramming or other therapeutic
maneuvers for the two lead systems are compared in Table
4. The number of observed clinical events not requiring
system revision for resolution related to each of these
categories is shown in parentheses . Inappropriate delivery of
antitachycardia therapy requiring system revision was sig-
nificantly more frequent in epicardial systems (p = 0 .0001) .
This was most often related to the coexistence of atria)
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Table 0. Percent of Patients With Clinical Complications
Requiring Either System Revision' or Resolution by Programming
Therapy Modificationt
Endocandial Epicardial
pValue
System System (endocardial
Recipients Recipients vs . epicardial
In = 605) (n = 616) complications)
lnetfecme (hemp)' 0 .6(o.2) 0.2 )) .)) 10 .2
Inappmpnate merapy
019 .2) 1 .8 (10 .2) 0 .001
Pavnpsensmg
0 .813 .81 2.6)9.4) 0.025
Inrection 3
.6(4 .8) (.6(2.3) 0.028
leade6a1,d 10.9(2
.8) 2.6 11A) 0.001
Gseemmr relined 0.5 (0
.3) 1 .0 (0.3) > 0.,
'Numbers w
.,he. parentheses . 'Numbers in parenthereu,
fibrillation or sensing problems . Complications related to
pacing or seining functions of the implantable cardioverter-
defibrillator system requiring surgical revision were also
more frequent in epicardial (2
.6%) than endocardial (£ .5%)
systems (p - 0.025). This was most often related to failure to
capture or attenuation of the sensing electrogram amplitude
with epicardial leads . Reprogramming or other intervention
for these problems was also needed more frequently in
epicardial thin endocardial systems (9 .4% vs . 3 .8%, p <
0.05) . In contrast
. implantable cardioverter-defibrillator sys-
tem infection was twice as frequent with endocardial as
epicardial systems (3 .6% vs. 1.6%, p = 0.028) . This is most
likely due to the multiple surgical fields or incisions, or both,
and the lead tunneling procedures in the former
. Lead
complications, most often dislodgment . were more frequent
in endocardial than epicardial systems (10.9f/r vs . 2.6% . p =
0 .001) . This was most frequently due to coronary sinus
locations,
Table 5 details the complications associated with primary
or secondary epicardial implantation of the implantable
cardioverter-defibrillator lead system . Note that the inci-
dence of pacing or sensing complications is significantly
higher for secondary epicardial implantation than for the
other category. Infection rates are also slightly higher than
for primary epicardial implantation, but this difference is not
significant.
Table 5. Compfcations of System Implantation Stratified by
Direct (primary) Implant or Crossover From Endocardial Attempt
(secondary implant)
-p
10.05
primary versus secendary epicardial implant . Data are percent
or pet melt.
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Table 3 . Patient Mortality
Endocoedial Epicardial
system Recipients System Recipients
In
= 605)
(n = 6(6)
Mean follow-up (me) 5 .9 9.5
Range (too) 0-28.6 0-33.3
Deaths 19(3.1^) 68114 .731
Mean age lyr) 63.9 62.8
CAD
(5 (789%x) 53 (77,9%)
NYHA functional classes
I
and
II 9(47.472) 41f60.3`%2
Mean
LVEF (9m)
23.9 30.0
Sudden
3(1587) 17(15.0")
Nonsudden 14
(737%) 29 (426%)
Noncardiac
2(10.5%)
'-2(3
,
4x)
penopemlive
5(26
.3%) 16(382%:
ICD Related 0 I(( .5r)
Primary Epicardial
Implant
in
= 535)
Secondary Epicadial
Implant
(n
= 81)
Ineffective therapy D 1 .2
leapprnpdate therapy 2.0 0
Focing(sensin8' ._ 5.0
Infection 2 .5
Lead rcla(ed 3,0 0
Generatorrol:led 0.9 1 .2
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Discussion
The development of programmable detection
and staged-
therapy pacemaker-defibrillator
devices and nonthoracot-
omy implantation procedures for the lead systems has been
anticipated and widely expected to improve
the attractive-
ness of device therapy for patients
at risk for recurrent
ventricular tachycardialventricular fibrillation
(13,14). How-
ever, early reports of prototype
systems and short-term
testing have raised technologic and clinical concerns (15).
These have mainly focused on the performance
of the
technologic hardware, maintenance of high efficacy in pre-
vention of recurrent sudden death and the complexity of
programmable generator used
. Although initial patient re-
ports from individual centers appeared favorable (11 .12,16),
this multicenter report provides the opportunity to objec-
tively assess all of these issues in a large, widely represen-
tative international study .
Importance of programmable features .
The inclusion of
programmable features and the use of a hybrid
pacemaker-
cardioverterdefibrillator device is supported by the data in
this study
. Independent therapy programming prescriptions
used in this study for ventricular tachycardia and ventricular
fibrillation support the concept of two tachycardia
detection
zones for monophasic implantable cardioverter-defibrillator
devices
. Low energy cardioversion was infrequently used in
the ventricular fibrillation zone because
Blow success in rapid
ventricular tachycardia
with monophasic shocks . In the
ventricular tachycardia zone, antitachycardia
pacing is
clearly preferred to low energy shocks. Programmable
tachycardia detection and antitachyeardia pacing can ac-
count for the relatively low exposure rate (<12%) o. ;patients
to shock therapy for ventricular tachycardia terming : "
The independent contribution of each feature compared with
nonprogrammable units cannot be completely assessed.
Antitachycardia pacing terminated 89% of ventricular tachy-
cardia episodes that would require shock termination
in
currently available devices . The efficacy of different pacing
modes (ramp or burst) proved comparable in clinical use in
contrast to previous suggestions (17) . There is also a low rate
of ventricular tachycardialventricular fibrillation therapy
delivery for atrial fibrillation
episodes in this study. This
specifically is dependent on detection
programming and is
lower than in previous reports (18). Noninvasive reprogram-
ming of either ventricular tachycardialventricularfibrillation
detection and therapy or pacing and sensing variables per-
mitted resolution of a variety of clinical problems after
initiating implantable cardioverter-defibrillator therapy (Ta-
ble 4). These are frequent and consume significant
physician
time and hospital resources for optimal device management .
Noninvasive programmed electrical stimulation permits ven-
tricular tachycardialventricular fibrillation initiation for de-
vice or spontaneous event evaluation during follow-up
with-
out catheter insertion and its attendant risks
. The availability
of data logs for tachycardia event reconstruction is an
important advance in clinical management of the patients
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with a defibrillator.
Most events could be correctly classified
on the basis of these data and the response to the therapy
delivered
. The availability of heart rate information alone
appears highly valuable. Additional variables,
such as stored
electrograms for part or all of the episode, are also helpful
adjuncts. These event data also establish the efficacy of a
multiprogrammable hybrid pacemaker-defibrillator pulse
generator for sudden death prevention.
Similar antiarrhyth-
mic efficacy with respect
to nonprogrammable devices and
comparable perioperative risk for epicardial lead
systems are
noted (2,3,18). Bradyarrhythmic death is largely eliminated
.
Total and sudden death survival with epicardial
systems is
comparable to previously reported data for
nonprogramma-
ble devices (1-3).
NoahxaaMmy iw hustsd a .
Endocandiat nontboracot-
omy lead systems can be definitively assessed from this
report and contrasted with epicardial systems . The periop-
erative mortality rate for device implantation is markedly
lower with the endocardial approach
. Although a random-
ized comparison was absent
from this study because of
difficulties in patient randomization
between thoencotosny
and nonthoracotomy methods, the observed
mortality rates
with endocardial systems are far lower than any
multicenter
prospective data available for epicardial lead systems
(4,5).
This difference exists whether the actual lead and device
systems implanted (as in all previous published literature) or
the intention-to-treat approach is used. The epicardial lead
system implantation mortality rate is comparableto previous
reports and is 4 .2% or 3.6%, depending on the two previous
analytic methodologies
(4) .
In a previous multicenter report
for a secondgeneration device it was 5 .4% . In a recent
compilation of reported multicenter data, Implantation mor-
Wky rate has ranged from 2%
to 10% (19) . The baseline
characteristics of the two patient populations
cannot explain
the difference in findings
ipso facto. The proportion of
sudden death victims was significantly
higher in the endo-
cardial implant recipients . This population has a poorer
survival rate than patients with recurrent ventricular tachy-
cardia and should adversely influence endocardial implant
outcome
. The difference in left ventricular ejection fraction
of 2 .2% in the two groups is
quite small and although
statistically significant, it has
a limited effect on survival.
There were no significant differences
in functional class,
which is a more important prognostic factor for cardiac
survival . The lower total mortality rate in endocardial lead
recipients can be explained, in our view, largely on the basis
of a lower perioperative mortality rate
. When perioperative
mortality is excluded, overall cardiac
and noncardiac sur-
vival is comparable in both groups . This also attests
to the
comparability of both patient
populations. Sudden death
survival benefit with longer-term
endocardial systems is
interesting and under current study
. It could, however,
merely reflect lower event rates in aggregate due to follow-
up duration differences. Nevertheless,
the overall clinical
outcome of endocardial lead recipients
is better than that
reported for epicardial lead recipients (19,20). The overall
JACC Vol. 23, No. r
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benefit in increased longevity conferred by implantable
cardioverter-defibrillator therapy in such patients is not
established from these data (19). Although this has been an
area
of
active debate, tiered-therapy devices and endocardial
lead systems should be the basis for any such comparison
with other antiarrhythmic therapies.
Stady limitations. The inability to implant endocardial
leads in 11 .8% of patients for long-term use is a current
limitation of such leads
. The use of simultaneous biphasic
shock waveforms with a triple endocardial lead system has
been shown to enhance efficacy and lower defibrillation
thresholds (21). Furthermore, optimizing the patch position
in the subcutaneous patch-endocardial lead configuration
can further reduce defibrillation energy requirements, and
early data suggest effective defibrillation at 15 J in nearly
all patients (22) . Alternatives such as change in lead polarity
er location can be used in refractory patients (23,24)
.
Pri-
mary endocardial implantation can be expected to further
reduce observed implantation risk to <_I%. These develop-
ments and our results establish the nonthoracotomy endo-
cardial approach as the primary method for implantable
cardioverter-defibrillator implantation . Future clinical trials
should use this approach to assess device performance and
patient outcome .
Epicardial lead system complications are in consonance
with previous reports. Additional issues related to pacing
performance are now apparent . Endocardial lead perfor-
mance appears to be
better in this category . Similar obser-
vations were noted with cardiac pacing with these two
approaches . In contrast, lead stability is better with directly
sutured epicardial leads compared with actively fixed or
floating endocardial leads . Improved endocardial lead stabil-
ity needs to be achieved by technologic development or
improved procedures at implantation. Infection appeared
more frequently in endocardial implantation, although it was
managed by drug therapy in many instances, but the system
revision rate of 3 .6%
requires improvement . Simplified im-
plantation procedures, as indicated earlier, may help to
reduce this problem.
Comdtddm. This study establishes the efficacy and safety
of
multiprogrammable hybrid pacemaker-cardioverter-
defibrillator devices used in conjunction with either epi-
cardial or endocardial leads . Endocardial lead systems
should be the implantation technique
of first choice because
of lower implantation mortality risk. Improved patient toler-
ance for device therapy can be anticipated from reduced
shock exposure
. Endocardial leads, by reducing patient
risk for device implantation mortality, can significantly
contribute to patient survival . These advances will make
device therapy a more attractive option for patients, physi-
cians and health care systems . Quantitative assessment of
benefitsof
defibrillator therapy in future clinical trials should
use tiered-therapy devices with endocardial leads to ensure
the best clinical outcome
of patients who receive a defibril-
lator
. Implanable cardioverter-defibrillator implantation
techniques used in a clinical trial or in cardiovascular prac-
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Lice have a direct impact on patient survival and quality of
life.
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